Manoj Pandey, PhD receives NIH R16 grant for Multiple Myeloma Research
April 26th, 2024
Manoj Pandey, associate professor of biomedical sciences, has received prestigious funding from th
e National Institutes of Health (NIH) to lead cutting-edge medical research on Multiple Myeloma.
The NIH R16 award, totaling $644,000, will fund a research project named "Novel Targeted Therapy for Refractory Multiple Myeloma." This effort aims to assess the ALDH isoforms that are accountable for the clonogenic capability and stem-like characteristics of multiple myeloma stem cells. The objective of this study is to investigate the impact of inhibiting ALDH on the development of resistance to bortezomib in a myeloma animal model. Additionally, the project attempts to uncover the specific role of ALDH isoforms in sustaining both the resistance and stemness of the myeloma cells. The funding from the NIH will enable the hiring of research assistants and the implementation of rigorous tests aimed at discovering new knowledge about ALDH inhibitors and their effects on myeloma resistance.
Dr. Pandey's innovative research can significantly impact the area of medicine, leading to the development of novel treatments and improved methods of patient care. Moreover, this accomplishment demonstrates CMSRU's continuous dedication to cultivating a culture of outstanding performance in research and innovation.
The co-investigators of this project are Dr. Tulin Budak-Alpdogan from Cooper University Health Care and MD Anderson Cancer Center at Cooper, Dr. Subash Jonnalagadda, and Dr. Yong Chen from Rowan University.